Want to take quizzes and track your credits?
In Reply We thank Marx and colleagues for their thoughtful comment on our recent article investigating the prevalence of posttraumatic stress disorder (PTSD) in postacute COVID-19 illness.1 We fully agree with the authors on the importance of assessing COVID-19–associated PTSD through the criterion-standard Clinician Administered PTSD Scale for DSM-5 (CAPS-5).2 Based on the CAPS-5, we found a 30.2% prevalence of PTSD in patients after acute COVID-19. Our results partly match the pooled PTSD prevalence of 21.94% (95% CI, 9.37-43.31) found in the meta-analysis by Cénat et al,3 which Marx and colleagues cited. However, this meta-analysis3 pooled actual patients with individuals from the general population. Hence, the higher PTSD prevalence found in our study in patients who experienced acute COVID-19 illness is not surprising and in line with the rate of 32.2% (95% CI, 23.7-42.0) reported by Rogers et al4 in postacute patients after previous coronavirus epidemics. Because the field is rapidly expanding, it is likely that many studies will be added and used to meta-analyze and synthesize published evidence.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Delfina Janiri, MD, Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Francesco Vito 1, 00168 Rome, Italy (email@example.com).
Published Online: June 2, 2021. doi:10.1001/jamapsychiatry.2021.1126
Conflict of Interest Disclosures: Dr Sani reports personal fees from Janssen, Angelini Spa, and Lundbeck. No other disclosures were reported.
You currently have no searches saved.